Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $4.9MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Brian Powl | Officer | Aug 21 '26 | Proposed Sale | $11.71 | 4,345 | $50,880 | — | Aug 21 04:41 PM |
| Bair Teresa Brophy | Chief Legal Officer | Aug 19 '26 | Sale | $12.63 | 31,487 | $397,681 | 195,444 | Aug 21 04:30 PM |
| Teresa Bair | Officer | Aug 19 '26 | Proposed Sale | $12.33 | 31,487 | $388,235 | — | Aug 19 04:24 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.